Molecular Pharmacology and Physiology
USF Health � College of Medicine
Login here to update your profile  
My Profile

Theresa Zesiewicz , MD

Primary Department: COLLEGE OF MEDICINE NEUROLOGY

Professor
COLLEGE OF MEDICINE NEUROLOGY
profile Image
Contacts
Email: tzesiewi@health.usf.edu
Phone: (813) 974-5633
Office: FOB, 4109
Mailing address
,
 
Education
  • MD, University Of Medicine And Dentistry Of New Jersey , United States - 1988.
    		•
     
     


    Selected Publications
  • Zesiewicz, TA.Sullivan, KL. Treatment of ataxia and imbalance with varenicline (chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14). Clinical neuropharmacology. 31(6): 363-5, .
  • Zesiewicz, TA.Hauser, RA.Freeman, A.Sullivan, KL.Miller, AM.Halim, T. Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease. Clinical neuropharmacology. 32(1): 48-50, .
  • Shimberg, WR.Patel, NB.Sullivan, KL.Hauser, RA.Zesiewicz, TA. Levetiracetam for stiff-person syndrome: report of 2 patients. Clinical neuropharmacology. 31(5): 301-2, .
  • Espay, AJ.Duker, AP.Chen, R.Okun, MS.Barrett, ET.Devoto, J.Zeilman, P.Gartner, M.Burton, N.Miranda, HA.Mandybur, GT.Zesiewicz, TA.Foote, KD.Revilla, FJ. Deep brain stimulation of the ventral intermediate nucleus of the thalamus in medically refractory orthostatic tremor: preliminary observations. Movement disorders : official journal of the Movement Disorder Society. 23(16): 2357-62, 2008.
  • Zesiewicz, TA.Sullivan, KL.Gooch, CL. Red flags to spot the parkinsonian variant of multiple system atrophy. Nature clinical practice. Neurology. 4(11): 596-7, 2008.
  • Zesiewicz, TA.Shimberg, WR.Hauser, RA.Robinson, W.Wilson, MC.Sullivan, KL. Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome Type 1. Clinical rheumatology. 27(3): 389-90, 2008.
  • Zesiewicz, TA.Sullivan, KL.Gooch, CL.Lynch, DR. Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix). Journal of clinical neuromuscular disease. 10(4): 191-3, 2009.
  • Saleh, IA.Zesiewicz, T.Xie, Y.Sullivan, KL.Miller, AM.Kuzmin-Nichols, N.Sanberg, PR.Garbuzova-Davis, S. Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression. Journal of neuroimmunology. 215(1-2): 96-101, 2009.
  • Zesiewicz, TA.Evatt, ML. Potential influences of complementary therapy on motor and non-motor complications in Parkinson's disease. CNS drugs. 23(10): 817-35, 2009.
  • Jahan, I.Hauser, RA.Sullivan, KL.Miller, A.Zesiewicz, TA. Sleep disorders in Parkinson's disease. Neuropsychiatric disease and treatment. 5(): 535-40, 2009.
  • Fleischman, D.Madan, G.Zesiewicz, TA.Fleischman, M. Stiff-person syndrome: commonly mistaken for hysterical paralysis. Clinical neurology and neurosurgery. 111(7): 644, 2009.
  • Garbuzova-Davis, S.Woods, RL.Louis, MK.Zesiewicz, TA.Kuzmin-Nichols, N.Sullivan, KL.Miller, AM.Hernandez-Ontiveros, DG.Sanberg, PR. Reduction of circulating endothelial cells in peripheral blood of ALS patients. PloS one. 5(5): e10614, 2010.
  • Zesiewicz, TA.Chari, A.Jahan, I.Miller, AM.Sullivan, KL. Overview of essential tremor. Neuropsychiatric disease and treatment. 6(): 401-8, 2010.

    • Grants
  • PROTOCOL #BVF-025-201 ($107,892.00, 06/01/2010-03/23/2015)
  • PROTOCOL#ROP111569 ($5,000.00, 01/01/2012-12/31/2014)
  • PROTOCOL#AL-108-231 ($13,000.00, 07/04/2011-07/03/2014)
  • PROTOCOL#AL-108-231 ($5,900.00, 07/04/2011-07/03/2014)
  • PROTOCOL#AL-108-231 ($1,294.00, 07/04/2011-07/03/2014)
  • PROTOCOL#AL-108-231 ($21,628.00, 07/04/2011-07/03/2014)
  • PROTOCOL#AL-108-231 ($3,459.00, 07/04/2011-07/03/2014)
  • PROTOCOL#ROP111569 ($11,483.00, 01/13/2012-06/30/2014)
  • PROTOCOL#ROP111569 ($3,020.00, 01/13/2012-06/30/2014)
  • PROTOCOL#ROP111569 ($10,298.00, 01/13/2012-06/30/2014)
  • PROTOCOL#ROP111569 ($10,000.00, 01/13/2012-06/30/2014)
  • PROTOCOL#ROP111662 ($7,709.00, 10/27/2011-06/30/2014)
  • PROTOCOL#ROP111662 ($13,616.00, 10/27/2011-06/30/2014)
  • PROTOCOL#ROP111662 ($3,695.00, 10/27/2011-06/30/2014)
  • PROTOCOL#ROP111662 ($11,272.00, 10/27/2011-06/30/2014)
  • PROTOCOL#ROP111662 ($3,959.00, 10/27/2011-06/30/2014)
  • PROTOCOL#ROP111662 ($2,018.00, 10/27/2011-06/30/2014)
  • PROTOCOL#ROP111662 ($3,772.00, 10/27/2011-06/30/2014)
  • PROTOCOL#ROP111662 ($11,172.00, 10/27/2011-06/30/2014)
  • PROTOCOL#ROP111662 ($10,000.00, 10/27/2011-06/30/2014)
  • PROTOCOL#ROP111662 ($7,092.00, 10/27/2011-06/30/2014)
  • PROTOCOL#ROP111662 ($1,568.00, 10/27/2011-06/30/2014)
  • FRIEDREICH'S ATAXIA RESEARCH CENTER ($161,000.00, 01/01/2011-12/31/2012)
  • CLINICAL RESEARCH CONSORTIUM FOR SPINOCEREBELLAR ATAXIAS ($15,004.00, 09/01/2010-08/31/2012)
  • PROTOCOL # VESI-9C01 ($202,850.00, 12/21/2009-08/09/2012)
  • PROTOCOL #GA00813T ($203,125.00, 07/30/2007-07/29/2012)
  • NATURAL HISTORY BIOMARKERS IN FRIEDREICH'S ATAXIA ($100,000.00, 04/01/2010-03/31/2012)
  • PROTOCOL# EMR62 225-013 ($15,600.00, 08/01/2003-12/31/2011)
  • A PILOT, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE I STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF VARENICLINE (CHANTIX) IN TREATING SPINOCEREBELLAR ATAXIA TYPES 1, 2, 3, AND 6. ($149,918.00, 07/01/2009-06/30/2011)
  • VALIDATION OF THE TRG ESSENTIAL TREMOR RATING SCALE (TETRAS) ($16,050.00, 06/09/2010-06/08/2011)
  • CLINICAL OUTCOME MEASURES IN FRIEDREICH'S ATAXIA ($61,063.00, 01/01/2010-12/31/2010)
  • CONTROLLED PILOT STUDY OF VARENICLINE (CHANTIX®) IN THE TREATMENT OF FRIEDREICH'S ATAXIA ($45,295.00, 09/10/2008-12/31/2010)
  • PROTOCOL #GA00813T ($125,419.00, 07/30/2007-11/30/2010)
  • PROTOCOL #GA00813T ($58,065.00, 07/30/2007-11/30/2010)
  • PROTOCOL #GA00813T ($3,600.00, 07/30/2007-11/30/2010)
  • CLINICAL RESEARCH CONSORTIUM FOR SPINOCEREBELLAR ATAXIAS (($15,004.00), 09/30/2009-08/31/2010)
  • CLINICAL RESEARCH CONSORTIUM FOR SPINOCEREBELLAR ATAXIAS ($15,004.00, 09/30/2009-08/31/2010)
  • CLINICAL RESEARCH CONSORTIUM FOR SPINOCEREBELLAR ATAXIAS ($15,004.00, 09/30/2009-08/31/2010)
  • PROTOCOL #248.538 ($31,945.00, 02/14/2005-07/28/2010)
  • EMD62-225-030 PADDY 0 ($428,350.00, 05/02/2005-05/01/2010)
  • EMD62-225-030 PADDY 0 ($219,245.00, 05/02/2005-05/01/2010)
  • DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PILOT STUDY OF VARENICLINE (CHANTIX®) IN THE TREATMENT OF FRIEDREICH'S ATAXIA ($174,278.00, 09/10/2008-03/09/2010)
  • PROTOCOL #07-021L ($94,107.00, 01/26/2009-01/25/2010)
  • PROTOCOL #S308.3.004 ($2,950.00, 04/29/2008-06/30/2008)
  • PROTOCOL #S308.3.009 ($2,950.00, 04/29/2008-06/30/2008)
  • 248-538 ($431,905.00, 02/14/2005-02/13/2008)
  • PROTOCOL #PO413580 BIPI 248.622 ($55,829.00, 09/01/2006-01/31/2008)
  • PROTOCOL #ELC200 A2305 ($36,546.00, 10/26/2005-05/29/2007)
  • PROTOCOL #ELC200 A2305 ($21,928.00, 10/26/2005-05/29/2007)
  • PROTOCOL #ELC200 A2305 ($70,732.00, 10/26/2005-05/29/2007)
  • MONITORING FORCE USA/MERCK ($111,700.00, 08/01/2003-12/31/2006)
  • PROTOCOL #101468/228 ($5,615.00, 01/14/2004-06/01/2006)
  • GLAXOSMITHKLINE/PROTOCOL #101468/228 ($114,023.00, 01/14/2004-06/01/2006)
  • MONITORING FORCE USA/MERCK - PROTOCOL #EMR 62 225 019 ($175,600.00, 10/18/2004-01/15/2006)
  • BOEHRINGER INGELHEIM/PROTOCOL 1198.100 ($218,530.00, 01/14/2004-06/30/2005)
  • NOVARTIS PHARMACEUTICALS CORPORATION PROTOCOL ENAB-356 ($19,096.00, 01/02/1997-07/31/2001)
  • SANDOZ PHARMACEUTICAL PROTOCOL B352 & B353 ($31,875.00, 12/15/1994-07/31/2000)


    • Profile last modified on 02/17/2012